{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:48:26Z","timestamp":1788904106564,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377154"],"award-info":[{"award-number":["22377154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62634-9","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:59:03Z","timestamp":1754740743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation"],"prefix":"10.1038","volume":"16","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0060-7121","authenticated-orcid":false,"given":"Xin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-2908","authenticated-orcid":false,"given":"Junjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S. C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-339X","authenticated-orcid":false,"given":"Xiaolin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-4398","authenticated-orcid":false,"given":"Taotao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"62634_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg, S., Disler, C. & Perego, P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer 21, 37\u201350 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"62634_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant Nivolumab plus Chemotherapy In Resectable Lung Cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62634_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang, Z. X. et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 40, 277\u2013288 (2022).","journal-title":"Cancer Cell"},{"key":"62634_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu, P. et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology 11, 2093518 (2022).","journal-title":"Oncoimmunology"},{"key":"62634_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343\u2013354 (2016).","journal-title":"Immunity"},{"key":"62634_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.trecan.2021.01.005","volume":"7","author":"G Petroni","year":"2021","unstructured":"Petroni, G., Kroemer, G. & Galluzzi, L. Immunogenic therapies drive CAR T cells towards superior efficacy. Trends Cancer 7, 179\u2013181 (2021).","journal-title":"Trends Cancer"},{"key":"62634_CR7","unstructured":"Bertini, I. G., Harry B., Lippard, S. J., Valentine, J. S. Bioinorganic Chemistry (University Science Books, 1994)."},{"key":"62634_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/j.2042-7158.1996.tb06002.x","volume":"48","author":"N Nagai","year":"1996","unstructured":"Nagai, N., Okuda, R., Kinoshita, M. & Ogata, H. Decomposition kinetics of cisplatin in human biological fluids. J. Pharm. Pharmacol. 48, 918\u2013924 (1996).","journal-title":"J. Pharm. Pharmacol."},{"key":"62634_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307\u2013320 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62634_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1039\/C6CS00860G","volume":"46","author":"M Cini","year":"2017","unstructured":"Cini, M., Bradshaw, T. D. & Woodward, S. Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chem. Soc. Rev. 46, 1040\u20131051 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"62634_CR11","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.1039\/D0SC04082G","volume":"11","author":"EJ Anthony","year":"2020","unstructured":"Anthony, E. J. et al. Metallodrugs are unique: opportunities and challenges of discovery and development. Chem. Sci. 11, 12888\u201312917 (2020).","journal-title":"Chem. Sci."},{"key":"62634_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/acscentsci.3c01340","volume":"10","author":"A Casini","year":"2024","unstructured":"Casini, A. & Pothig, A. Metals in cancer research: beyond platinum metallodrugs. ACS Cent. Sci. 10, 242\u2013250 (2024).","journal-title":"ACS Cent. Sci."},{"key":"62634_CR13","doi-asserted-by":"publisher","first-page":"6612","DOI":"10.1021\/acs.chemrev.2c00649","volume":"123","author":"RT Mertens","year":"2023","unstructured":"Mertens, R. T., Gukathasan, S., Arojojoye, A. S., Olelewe, C. & Awuah, S. G. Next generation gold drugs and probes: chemistry and biomedical applications. Chem. Rev. 123, 6612\u20136667 (2023).","journal-title":"Chem. Rev."},{"key":"62634_CR14","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1039\/C5CS00132C","volume":"44","author":"T Zou","year":"2015","unstructured":"Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J. & Che, C.-M. Chemical biology of anticancer gold(III) and gold(I) complexes. Chem. Soc. Rev. 44, 8786\u20138801 (2015).","journal-title":"Chem. Soc. Rev."},{"key":"62634_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41570-018-0018-6","volume":"2","author":"L Riccardi","year":"2018","unstructured":"Riccardi, L., Genna, V. & De Vivo, M. Metal-ligand interactions in drug design. Nat. Rev. Chem. 2, 100\u2013112 (2018).","journal-title":"Nat. Rev. Chem."},{"key":"62634_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cbpa.2017.10.014","volume":"43","author":"T Zou","year":"2018","unstructured":"Zou, T. et al. Anticancer metal-N-heterocyclic carbene complexes of gold, platinum and palladium. Curr. Opin. Chem. Biol. 43, 30\u201336 (2018).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"62634_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/acs.accounts.3c00037","volume":"56","author":"J Jiang","year":"2023","unstructured":"Jiang, J., Xiong, X. & Zou, T. Modulating the chemical reactivity of gold complexes in living systems: from concept to biomedical applications. Acc. Chem. Res. 56, 1043\u20131056 (2023).","journal-title":"Acc. Chem. Res."},{"key":"62634_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1073\/pnas.1915202117","volume":"117","author":"KC Tong","year":"2020","unstructured":"Tong, K. C. et al. An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols. Proc. Natl. Acad. Sci. USA. 117, 1321\u20131329 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"62634_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1039\/D2SC04707A","volume":"14","author":"A Johnson","year":"2023","unstructured":"Johnson, A. et al. The anti-breast cancer stem cell properties of gold(I)-non-steroidal anti-inflammatory drug complexes. Chem. Sci. 14, 557\u2013565 (2023).","journal-title":"Chem. Sci."},{"key":"62634_CR20","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1021\/acs.jmedchem.3c00238","volume":"66","author":"AS Arojojoye","year":"2023","unstructured":"Arojojoye, A. S. et al. Serum-Stable Gold(III) Bisphosphine complex induces mild mitochondrial uncoupling and in vivo antitumor potency in triple negative breast cancer. J. Med. Chem. 66, 7868\u20137879 (2023).","journal-title":"J. Med. Chem."},{"key":"62634_CR21","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.1039\/D1SC01418H","volume":"12","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. Anticancer gold(III)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition. Chem. Sci. 12, 7467\u20137479 (2021).","journal-title":"Chem. Sci."},{"key":"62634_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405\u2013408 (2017).","journal-title":"Nat. Med."},{"key":"62634_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s43018-020-0024-8","volume":"1","author":"RL Beijersbergen","year":"2020","unstructured":"Beijersbergen, R. L. Old drugs with new tricks. Nat. Cancer 1, 153\u2013155 (2020).","journal-title":"Nat. Cancer"},{"key":"62634_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235\u2013248 (2020).","journal-title":"Nat. Cancer"},{"key":"62634_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s43018-020-0030-x","volume":"1","author":"B Gyawali","year":"2020","unstructured":"Gyawali, B., Bouche, G., Crisp, N. & Andre, N. Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nat. Cancer 1, 142\u2013145 (2020).","journal-title":"Nat. Cancer"},{"key":"62634_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41564-020-00802-x","volume":"5","author":"SF Yuan","year":"2020","unstructured":"Yuan, S. F. et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat. Microbiol. 5, 1439\u20131448 (2020).","journal-title":"Nat. Microbiol."},{"key":"62634_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris, I. S. et al. Glutathione and Thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211\u2013222 (2015).","journal-title":"Cancer Cell"},{"key":"62634_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ccell.2016.02.012","volume":"29","author":"SA Ali","year":"2016","unstructured":"Ali, S. A., Justilien, V., Jamieson, L., Murray, N. R. & Fields, A. P. Protein Kinase C\u03b9 drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 29, 367\u2013378 (2016).","journal-title":"Cancer Cell"},{"key":"62634_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes, J. D., Dinkova-Kostova, A. T. & Tew, K. D. Oxidative stress in cancer. Cancer Cell 38, 167\u2013197 (2020).","journal-title":"Cancer Cell"},{"key":"62634_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/med.20168","volume":"30","author":"S Nobili","year":"2010","unstructured":"Nobili, S. et al. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev. 30, 550\u2013580 (2010).","journal-title":"Med. Res. Rev."},{"key":"62634_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/djy149","volume":"111","author":"E Hatem","year":"2019","unstructured":"Hatem, E. et al. Auranofin\/Vitamin C: A novel drug combination targeting triple-negative breast cancer. J. Natl. Cancer Inst. 111, 597\u2013608 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"62634_CR32","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/hep.30467","volume":"69","author":"D Lee","year":"2019","unstructured":"Lee, D. et al. Induction of oxidative stress through inhibition of Thioredoxin Reductase 1 Is an effective therapeutic approach for hepatocellular carcinoma. Hepatology 69, 1768\u20131786 (2019).","journal-title":"Hepatology"},{"key":"62634_CR33","doi-asserted-by":"publisher","first-page":"215323","DOI":"10.1016\/j.ccr.2023.215323","volume":"493","author":"SY Shen","year":"2023","unstructured":"Shen, S. Y., Shen, J., Luo, Z., Wang, F. D. & Min, J. X. Molecular mechanisms and clinical implications of the gold drug auranofin. Coord. Chem. Rev. 493, 215323 (2023).","journal-title":"Coord. Chem. Rev."},{"key":"62634_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/med.21872","volume":"42","author":"T Gamberi","year":"2022","unstructured":"Gamberi, T. et al. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Med. Res. Rev. 42, 1111\u20131146 (2022).","journal-title":"Med. Res. Rev."},{"key":"62634_CR35","first-page":"5486","volume":"46","author":"SJ Berners-Price","year":"1986","unstructured":"Berners-Price, S. J. et al. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res. 46, 5486\u20135493 (1986).","journal-title":"Cancer Res."},{"key":"62634_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1155\/MBD.1994.107","volume":"1","author":"PJ Sadler","year":"1994","unstructured":"Sadler, P. J. & Sue, R. E. The chemistry of gold drugs. Met. -Based Drugs 1, 107\u2013144 (1994).","journal-title":"Met. -Based Drugs"},{"key":"62634_CR37","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1021\/cr980431o","volume":"99","author":"CF Shaw","year":"1999","unstructured":"Shaw, C. F. Gold-based therapeutic agents. Chem. Rev. 99, 2589\u20132600 (1999).","journal-title":"Chem. Rev."},{"key":"62634_CR38","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1158\/0008-5472.CAN-06-3017","volume":"66","author":"V Milacic","year":"2006","unstructured":"Milacic, V. et al. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res. 66, 10478\u201310486 (2006).","journal-title":"Cancer Res."},{"key":"62634_CR39","doi-asserted-by":"publisher","first-page":"12570","DOI":"10.1021\/ja804027j","volume":"130","author":"JL Hickey","year":"2008","unstructured":"Hickey, J. L. et al. Mitochondria-targeted chemotherapeutics: The rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc. 130, 12570\u201312571 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"62634_CR40","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ccr.2009.02.019","volume":"253","author":"I Ott","year":"2009","unstructured":"Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev. 253, 1670\u20131681 (2009).","journal-title":"Coord. Chem. Rev."},{"key":"62634_CR41","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/med.21589","volume":"39","author":"SJ Ralph","year":"2019","unstructured":"Ralph, S. J., Nozuhur, S., RA, A. L., Rodriguez-Enriquez, S. & Moreno-Sanchez, R. Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers. Med. Res. Rev. 39, 2397\u20132426 (2019).","journal-title":"Med. Res. Rev."},{"key":"62634_CR42","doi-asserted-by":"publisher","first-page":"16795","DOI":"10.1002\/anie.202006212","volume":"59","author":"J-J Zhang","year":"2020","unstructured":"Zhang, J.-J. et al. A multitarget Gold(I) complex induces cytotoxicity related to Aneuploidy in HCT-116 colorectal carcinoma cells. Angew. Chem. Int. Ed. 59, 16795\u201316800 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR43","doi-asserted-by":"publisher","first-page":"104822","DOI":"10.1016\/j.jddst.2023.104822","volume":"87","author":"L Cosottini","year":"2023","unstructured":"Cosottini, L. et al. Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin. J. Drug. Deliv. Sci. Tec. 87, 104822\u2013104831 (2023).","journal-title":"J. Drug. Deliv. Sci. Tec."},{"key":"62634_CR44","doi-asserted-by":"publisher","first-page":"e202218000","DOI":"10.1002\/anie.202218000","volume":"62","author":"G Moreno-Alcantar","year":"2023","unstructured":"Moreno-Alcantar, G., Picchetti, P. & Casini, A. Gold complexes in anticancer therapy: from new design principles to particle-based delivery systems. Angew. Chem. Int. Ed. 62, e202218000 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR45","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.cell.2023.04.026","volume":"186","author":"JB Zhang","year":"2023","unstructured":"Zhang, J. B. et al. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria pathway. Cell 186, 2361\u20132379 (2023).","journal-title":"Cell"},{"key":"62634_CR46","doi-asserted-by":"publisher","first-page":"96062","DOI":"10.18632\/oncotarget.21708","volume":"8","author":"I Landini","year":"2017","unstructured":"Landini, I. et al. Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget 8, 96062\u201396078 (2017).","journal-title":"Oncotarget"},{"key":"62634_CR47","doi-asserted-by":"publisher","first-page":"213905","DOI":"10.1016\/j.ccr.2021.213905","volume":"438","author":"T Gamberi","year":"2021","unstructured":"Gamberi, T., Pratesi, A., Messori, L. & Massai, L. Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds. Coord. Chem. Rev. 438, 213905 (2021).","journal-title":"Coord. Chem. Rev."},{"key":"62634_CR48","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.redox.2022.102294","volume":"52","author":"G Chiappetta","year":"2022","unstructured":"Chiappetta, G. et al. Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780). Redox Biol. 52, 102294 (2022).","journal-title":"Redox Biol."},{"key":"62634_CR49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0006-2952(86)90078-X","volume":"35","author":"RM Snyder","year":"1986","unstructured":"Snyder, R. M., Mirabelli, C. K. & Crooke, S. T. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem. Pharmacol. 35, 923\u2013932 (1986).","journal-title":"Biochem. Pharmacol."},{"key":"62634_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0162-0134(87)80062-4","volume":"30","author":"MT Coffer","year":"1987","unstructured":"Coffer, M. T., Shaw, C. F., Hormann, A. L., Mirabelli, C. K. & Crooke, S. T. Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation. J. Inorg. Biochem. 30, 177\u2013187 (1987).","journal-title":"J. Inorg. Biochem."},{"key":"62634_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/ic9414280","volume":"35","author":"JR Roberts","year":"1996","unstructured":"Roberts, J. R., Xiao, J., Schliesman, B., Parsons, D. J. & Shaw, C. F. Kinetics and mechanism of the reaction between serum albumin and auranofin (and its isopropyl analogue) in vitro. Inorg. Chem. 35, 424\u2013433 (1996).","journal-title":"Inorg. Chem."},{"key":"62634_CR52","first-page":"94","volume":"41","author":"TM Simon","year":"1981","unstructured":"Simon, T. M., Kunishima, D. H., Vibert, G. J. & Lorber, A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res. 41, 94\u201397 (1981).","journal-title":"Cancer Res"},{"key":"62634_CR53","first-page":"32","volume":"45","author":"CK Mirabelli","year":"1985","unstructured":"Mirabelli, C. K. et al. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 45, 32\u201339 (1985).","journal-title":"Cancer Res"},{"key":"62634_CR54","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1182\/blood.V122.21.3819.3819","volume":"122","author":"NS Saba","year":"2013","unstructured":"Saba, N. S. et al. Auranofin induces a reversible in-vivo stress response that correlates with a transient clinical effect in patients with chronic lymphocytic leukemia. Blood 122, 3819\u20133819 (2013).","journal-title":"Blood"},{"key":"62634_CR55","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1111\/bph.14773","volume":"176","author":"ME Halatsch","year":"2019","unstructured":"Halatsch, M. E. et al. Bcl-2\/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br. J. Pharmacol. 176, 3681\u20133694 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"62634_CR56","first-page":"vdab075","volume":"3","author":"ME Halatsch","year":"2021","unstructured":"Halatsch, M. E. et al. A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neurooncol. Adv. 3, vdab075 (2021).","journal-title":"Neurooncol. Adv."},{"key":"62634_CR57","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott, Z. et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194\u2013199 (2017).","journal-title":"Nature"},{"key":"62634_CR58","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.ccr.2009.02.026","volume":"253","author":"A Bindoli","year":"2009","unstructured":"Bindoli, A. et al. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 253, 1692\u20131707 (2009).","journal-title":"Coord. Chem. Rev."},{"key":"62634_CR59","unstructured":"Casini, A., Wai-Yin Sun, R. & Ott, I. Metallo-Drugs: Development and Action of Anticancer Agents (De Gruyter, 2018)."},{"key":"62634_CR60","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1021\/acs.inorgchem.9b03072","volume":"59","author":"IJ Pickering","year":"2020","unstructured":"Pickering, I. J. et al. Direct observation of Methylmercury and Auranofin binding to Selenocysteine in Thioredoxin Reductase. Inorg. Chem. 59, 2711\u20132718 (2020).","journal-title":"Inorg. Chem."},{"key":"62634_CR61","doi-asserted-by":"publisher","first-page":"101646","DOI":"10.1016\/j.redox.2020.101646","volume":"36","author":"S Busker","year":"2020","unstructured":"Busker, S., Page, B. & Arn\u00e9r, E. S. J. To inhibit TrxR1 is to inactivate STAT3\u2013Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors. Redox Biol. 36, 101646 (2020).","journal-title":"Redox Biol."},{"key":"62634_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/0008-5472.CAN-18-1938","volume":"79","author":"X Yan","year":"2019","unstructured":"Yan, X. et al. Inhibition of Thioredoxin\/Thioredoxin Reductase induces synthetic lethality in lung cancers with compromised Glutathione Homeostasis. Cancer Res 79, 125\u2013132 (2019).","journal-title":"Cancer Res"},{"key":"62634_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ijc.32410","volume":"146","author":"PV Raninga","year":"2020","unstructured":"Raninga, P. V. et al. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. Int. J. Cancer 146, 123\u2013136 (2020).","journal-title":"Int. J. Cancer"},{"key":"62634_CR64","doi-asserted-by":"publisher","first-page":"eabq5931","DOI":"10.1126\/scitranslmed.abq5931","volume":"14","author":"N Yin","year":"2022","unstructured":"Yin, N. et al. Protein kinase C\u03b9 mediates immunosuppression in lung adenocarcinoma. Sci. Transl. Med. 14, eabq5931 (2022).","journal-title":"Sci. Transl. Med."},{"key":"62634_CR65","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/tox.23828","volume":"38","author":"SY Chen","year":"2023","unstructured":"Chen, S. Y. et al. Diphenyl disulfide potentiates the apoptosis of breast cancer cells through Bax proteolytic activation with accompanying autophagy. Environ. Toxicol. 38, 2022\u20132030 (2023).","journal-title":"Environ. Toxicol."},{"key":"62634_CR66","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrm.2016.110","volume":"17","author":"OCM Sibon","year":"2016","unstructured":"Sibon, O. C. M. & Strauss, E. Coenzyme A: to make it or uptake it?. Nat. Rev. Mol. Cell Biol. 17, 605\u2013606 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"62634_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nutres.2004.12.009","volume":"25","author":"MP McRae","year":"2005","unstructured":"McRae, M. P. Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability. Nutr. Res. 25, 319\u2013333 (2005).","journal-title":"Nutr. Res."},{"key":"62634_CR68","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/nchembio.1906","volume":"11","author":"B Srinivasan","year":"2015","unstructured":"Srinivasan, B. et al. Extracellular 4\u2019-phosphopantetheine is a source for intracellular coenzyme A synthesis. Nat. Chem. Biol. 11, 784\u2013792 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"62634_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/15027732.1986.12461436","volume":"63","author":"NL Gottlieb","year":"1986","unstructured":"Gottlieb, N. L. Pharmacology of auranofin: overview and update. Scand. J. Rheumatol. Suppl. 63, 19\u201328 (1986).","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"62634_CR70","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nm.2758","volume":"18","author":"A Debnath","year":"2012","unstructured":"Debnath, A. et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 18, 956\u2013960 (2012).","journal-title":"Nat. Med."},{"key":"62634_CR71","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0002-9343(83)90483-7","volume":"75","author":"K Blocka","year":"1983","unstructured":"Blocka, K. Auranofin versus injectable gold: Comparison of pharmacokinetic properties. Am. J. Med. 75, 114\u2013122 (1983).","journal-title":"Am. J. Med."},{"key":"62634_CR72","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0002-9343(83)90481-3","volume":"75","author":"DT Walz","year":"1983","unstructured":"Walz, D. T., DiMartino, M. J., Griswold, D. E., Intoccia, A. P. & Flanagan, T. L. Biologic actions and pharmacokinetic studies of auranofin. Am. J. Med. 75, 90\u2013108 (1983).","journal-title":"Am. J. Med."},{"key":"62634_CR73","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1074\/jbc.TM117.000259","volume":"293","author":"A Solmonson","year":"2018","unstructured":"Solmonson, A. & DeBerardinis, R. J. Lipoic acid metabolism and mitochondrial redox regulation. J. Biol. Chem. 293, 7522\u20137530 (2018).","journal-title":"J. Biol. Chem."},{"key":"62634_CR74","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov, P. et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375, 1254\u20131261 (2022).","journal-title":"Science"},{"key":"62634_CR75","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2174\/0929867043365387","volume":"11","author":"AR Smith","year":"2004","unstructured":"Smith, A. R., Shenvi, S. V., Widlansky, M., Suh, J. H. & Hagen, T. M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem. 11, 1135\u20131146 (2004).","journal-title":"Curr. Med. Chem."},{"key":"62634_CR76","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1039\/C9CS00373H","volume":"49","author":"A Steinbrueck","year":"2020","unstructured":"Steinbrueck, A. et al. Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents. Chem. Soc. Rev. 49, 3726\u20133747 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"62634_CR77","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"62634_CR78","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1073\/pnas.1421002112","volume":"112","author":"Y Hong","year":"2015","unstructured":"Hong, Y., Lai, Y., Chan, G. & Sun, H. Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells. Proc. Natl. Acad. Sci. USA 112, 3211\u20133216 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62634_CR79","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1073\/pnas.1503858112","volume":"112","author":"I Romero-Canel\u00f3n","year":"2015","unstructured":"Romero-Canel\u00f3n, I. & Sadler, P. J. Systems approach to metal-based pharmacology. Proc. Natl. Acad. Sci. USA 112, 4187\u20134188 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62634_CR80","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/acsmedchemlett.7b00162","volume":"8","author":"T Marzo","year":"2017","unstructured":"Marzo, T. et al. Auranofin, Et3PAuCl, and Et3PAuI ARE HIGHLY CYTOTOXIC ON COLORECTAL CANCER CELLS: A CHEMICAL AND BIOLOGICAL Study. ACS Med. Chem. Lett. 8, 997\u20131001 (2017).","journal-title":"ACS Med. Chem. Lett."},{"key":"62634_CR81","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acsmedchemlett.9b00007","volume":"10","author":"T Marzo","year":"2019","unstructured":"Marzo, T. et al. Replacement of the Thiosugar of Auranofin with Iodide enhances the anticancer potency in a mouse model of ovarian cancer. ACS Med. Chem. Lett. 10, 656\u2013660 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"62634_CR82","doi-asserted-by":"publisher","first-page":"8408","DOI":"10.1021\/acs.jmedchem.0c00754","volume":"63","author":"P Ertl","year":"2020","unstructured":"Ertl, P., Altmann, E. & McKenna, J. M. The most common functional groups in bioactive molecules and how their popularity has evolved over time. J. Med. Chem. 63, 8408\u20138418 (2020).","journal-title":"J. Med. Chem."},{"key":"62634_CR83","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"62634_CR84","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1021\/jacs.2c09820","volume":"145","author":"Y Marciano","year":"2023","unstructured":"Marciano, Y. et al. Encapsulation of gold-based anticancer agents in Protease-degradable peptide nanofilaments enhances their potency. J. Am. Chem. Soc. 145, 234\u2013246 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"62634_CR85","doi-asserted-by":"publisher","first-page":"8718","DOI":"10.1039\/D4RA01617C","volume":"14","author":"LK Batchelor","year":"2024","unstructured":"Batchelor, L. K., De Falco, L., Dyson, P. J. & Davey, C. A. Viral peptide conjugates for metal-warhead delivery to chromatin. RSC Adv. 14, 8718\u20138725 (2024).","journal-title":"RSC Adv."},{"key":"62634_CR86","doi-asserted-by":"crossref","unstructured":"Cosottini, L. et al. Unlocking the power of human ferritin: enhanced drug delivery of Aurothiomalate in A2780 ovarian cancer cells. Angew. Chem. Int. Ed. 63, e202410791 (2024).","DOI":"10.1002\/anie.202410791"},{"key":"62634_CR87","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1021\/jm990492u","volume":"43","author":"L Messori","year":"2000","unstructured":"Messori, L. et al. Gold(III) complexes as potential antitumor agents: Solution chemistry and cytotoxic properties of some selected gold(III) compounds. J. Med. Chem. 43, 3541\u20133548 (2000).","journal-title":"J. Med. Chem."},{"key":"62634_CR88","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1039\/D1CS00933H","volume":"51","author":"YL Lu","year":"2022","unstructured":"Lu, Y. L. et al. Recent development of gold(I) and gold(III)complexes as therapeutic agents for cancer diseases. Chem. Soc. Rev. 51, 5518\u20135556 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"62634_CR89","doi-asserted-by":"publisher","first-page":"14524","DOI":"10.1002\/anie.201805727","volume":"57","author":"D Wragg","year":"2018","unstructured":"Wragg, D. et al. On the mechanism of Gold\/NHC compounds binding to DNA G-Quadruplexes: combined metadynamics and biophysical methods. Angew. Chem. Int. Ed. 57, 14524\u201314528 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR90","doi-asserted-by":"publisher","first-page":"14424","DOI":"10.1021\/acs.jmedchem.2c00737","volume":"65","author":"AAA Sulaiman","year":"2022","unstructured":"Sulaiman, A. A. A. et al. Design, synthesis, and preclinical activity in ovarian cancer models of new Phosphanegold(I)-N-heterocyclic Carbene complexes. J. Med. Chem. 65, 14424\u201314440 (2022).","journal-title":"J. Med. Chem."},{"key":"62634_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202217233","volume":"62","author":"T Babu","year":"2023","unstructured":"Babu, T. et al. Oral anticancer heterobimetallic PtIV\u2212AuI complexes show high in vivo activity and low toxicity. Angew. Chem. Int. Ed. 62, e202217233 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR92","doi-asserted-by":"publisher","first-page":"8895","DOI":"10.1002\/anie.201202939","volume":"51","author":"A Meyer","year":"2012","unstructured":"Meyer, A. et al. On the biological properties of alkynyl phosphine Gold(I) complexes. Angew. Chem. Int. Ed. 51, 8895\u20138899 (2012).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR93","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1039\/C5SC01753J","volume":"6","author":"J Fern\u00e1ndez-Gallardo","year":"2015","unstructured":"Fern\u00e1ndez-Gallardo, J. et al. Heterometallic titanium\u2013gold complexes inhibit renal cancer cells in vitro and in vivo. Chem. Sci. 6, 5269\u20135283 (2015).","journal-title":"Chem. Sci."},{"key":"62634_CR94","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41557-023-01199-w","volume":"15","author":"X-Q Zhou","year":"2023","unstructured":"Zhou, X.-Q. et al. In vivo metallophilic self-assembly of a light-activated anticancer drug. Nat. Chem. 15, 980\u2013987 (2023).","journal-title":"Nat. Chem."},{"key":"62634_CR95","doi-asserted-by":"publisher","first-page":"783","DOI":"10.31635\/ccschem.023.202303190","volume":"6","author":"X-Q Zhou","year":"2023","unstructured":"Zhou, X.-Q. et al. Multitarget Thiol-Activated Tetrapyridyl Gold(III) complexes for hypoxic cancer therapy. CCS Chem. 6, 783\u2013797 (2023).","journal-title":"CCS Chem."},{"key":"62634_CR96","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1021\/jacsau.0c00104","volume":"1","author":"X-Q Zhou","year":"2021","unstructured":"Zhou, X.-Q. et al. Rollover Cyclometalation vs nitrogen coordination in Tetrapyridyl Anticancer Gold(III) complexes: effect on protein interaction and toxicity. JACS Au 1, 380\u2013395 (2021).","journal-title":"JACS Au"},{"key":"62634_CR97","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.cbpa.2022.102250","volume":"72","author":"JE L\u00f3pez-Hern\u00e1ndez","year":"2023","unstructured":"L\u00f3pez-Hern\u00e1ndez, J. E. & Contel, M. Promising heterometallic compounds as anticancer agents: Recent studies in vivo. Curr. Opin. Chem. Biol. 72, 102250 (2023).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"62634_CR98","doi-asserted-by":"publisher","first-page":"15660","DOI":"10.1002\/anie.201906423","volume":"58","author":"LK Batchelor","year":"2019","unstructured":"Batchelor, L. K. et al. Crosslinking allosteric sites on the nucleosome. Angew. Chem. Int. Ed. 58, 15660\u201315664 (2019).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14860","volume":"8","author":"Z Adhireksan","year":"2017","unstructured":"Adhireksan, Z. et al. Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat. Commun. 8, 14860 (2017).","journal-title":"Nat. Commun."},{"key":"62634_CR100","doi-asserted-by":"publisher","first-page":"102703","DOI":"10.1016\/j.redox.2023.102703","volume":"62","author":"DM Cheff","year":"2023","unstructured":"Cheff, D. M. et al. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1. Redox Biol. 62, 102703 (2023).","journal-title":"Redox Biol."},{"key":"62634_CR101","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nchem.2706","volume":"9","author":"N Busschaert","year":"2017","unstructured":"Busschaert, N. et al. A synthetic ion transporter that disrupts autophagy and induces apoptosis by perturbing cellular chloride concentrations. Nat. Chem. 9, 667\u2013675 (2017).","journal-title":"Nat. Chem."},{"key":"62634_CR102","doi-asserted-by":"publisher","first-page":"20536","DOI":"10.1021\/jacs.0c09753","volume":"142","author":"S Sen","year":"2020","unstructured":"Sen, S. et al. Rationally designed Redox-Active Au(I) N-heterocyclic carbene: an immunogenic cell death inducer. J. Am. Chem. Soc. 142, 20536\u201320541 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"62634_CR103","doi-asserted-by":"publisher","first-page":"704","DOI":"10.7326\/0003-4819-100-5-704","volume":"100","author":"PJ Loehrer","year":"1984","unstructured":"Loehrer, P. J. & Einhorn, L. H. Cisplatin. Ann. Intern. Med. 100, 704\u2013713 (1984).","journal-title":"Ann. Intern. Med."},{"key":"62634_CR104","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7326\/0003-4819-95-5-628","volume":"95","author":"JD Blachley","year":"1981","unstructured":"Blachley, J. D. & Hill, J. B. Renal and electrolyte disturbances associated with Cisplatin. Ann. Intern. Med. 95, 628\u2013632 (1981).","journal-title":"Ann. Intern. Med."},{"key":"62634_CR105","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/0006-2952(85)90795-6","volume":"34","author":"PT Daley-Yates","year":"1985","unstructured":"Daley-Yates, P. T. & McBrien, D. C. H. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem. Pharmacol. 34, 2363\u20132369 (1985).","journal-title":"Biochem. Pharmacol."},{"key":"62634_CR106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona, D. J. et al. A systematic review of strategies to prevent Cisplatin-Induced Nephrotoxicity.  Oncologist 22, 609\u2013619 (2017).","journal-title":"Oncologist"},{"key":"62634_CR107","doi-asserted-by":"publisher","first-page":"e2100275","DOI":"10.1200\/GO.21.00275","volume":"8","author":"P Sainamthip","year":"2022","unstructured":"Sainamthip, P., Saichaemchan, S., Satirapoj, B. & Prasongsook, N. The effect of intravenous mannitol combined with normal saline in preventing cisplatin-induced nephrotoxicity: a randomized, double-blind, placebo-controlled trial. JCO Glob. Oncol. 8, e2100275 (2022).","journal-title":"JCO Glob. Oncol."},{"key":"62634_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12529-3","volume":"10","author":"DM Cai","year":"2019","unstructured":"Cai, D. M. et al. ROR gamma is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat. Commun. 10, 4621 (2019).","journal-title":"Nat. Commun."},{"key":"62634_CR109","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1126\/science.6429854","volume":"225","author":"K Tepperman","year":"1984","unstructured":"Tepperman, K. et al. Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science 225, 430\u2013432 (1984).","journal-title":"Science"},{"key":"62634_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202212689","volume":"61","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. Organogold(III) complexes display conditional photoactivities: evolving from photodynamic into photoactivated chemotherapy in response to o-2 consumption for robust cancer therapy. Angew. Chem. Int. Ed. 61, e202212689 (2022).","journal-title":"Angew. Chem. Int. Ed."},{"key":"62634_CR111","doi-asserted-by":"publisher","first-page":"1204926","DOI":"10.3389\/fendo.2023.1204926","volume":"14","author":"M Jiang","year":"2023","unstructured":"Jiang, M. et al. Verification of cuproptosis-related diagnostic model associated with immune infiltration in rheumatoid arthritis. Front. Endocrinol. 14, 1204926 (2023).","journal-title":"Front. Endocrinol."},{"key":"62634_CR112","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/15548627.2015.1009787","volume":"11","author":"K Liu","year":"2015","unstructured":"Liu, K. et al. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Autophagy 11, 271\u2013284 (2015).","journal-title":"Autophagy"},{"key":"62634_CR113","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-023-02720-2","volume":"42","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J. Exp. Clin. Cancer Res. 42, 142 (2023).","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62634-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:53:44Z","timestamp":1757346824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62634-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62634"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62634-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.25.577173","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.W., X.X., A.S.C.C., and T.Z. hold patents related to combo treatment by auranofin and thiols\/disulfides. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7347"}}